PP.20.15

Gómez‐Sánchez, Leticia; Patino-Alonso, María C.; Agudo‐Conde, Cristina; Gómez‐Sánchez, Marta; Rodríguez‐Sánchez, Elena; Maderuelo‐Fernández, José Ángel; Rigo, Fernando; Ramos-Blanes, R.; Martí, Ruth; Parramont, D.; Frontera, Guillermo; Gomez-Marcos, M.

doi:10.1097/01.hjh.0000468327.83793.3c

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Arterial stiffness differs systemically, with peripheral and muscular vessels presenting as stiffer compared with the ascending or abdominal aorta. 25,26 For example, the carotid artery has lower vessel distensibility compared with Abbreviations: BMI, body mass index; BFV, blood flow velocity; BP, blood pressure; CVC, cerebrovascular conductance; F, female; HCL, high-density lipoprotein; LDL, low-density lipoprotein; M, male; MetS, metabolic syndrome; PWV, pulse wave velocity.…”

Section: Discussionmentioning

confidence: 99%

Impacts of Metabolic Syndrome Scores on Cerebrovascular Conductance Are Mediated by Arterial Stiffening

Pasha

Birdsill

Oleson

et al. 2017

American Journal of Hypertension

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Impacts of Metabolic Syndrome Scores on Cerebrovascular Conductance Are Mediated by Arterial Stiffening

Pasha

Birdsill

Oleson

et al. 2017

American Journal of Hypertension

View full text Add to dashboard Cite

show abstract

“…6,7 The cardio-ankle vascular index (CAVI), an arterial stiffness parameter, has been developed to assess the stiffness of the arterial tree from the aortic origin to the ankle independent of blood pressure (BP). 8 This parameter is known to be high in individuals with various atherosclerotic diseases including coronary artery disease, 9 cerebral infarction, 10 carotid sclerosis 11 and chronic kidney disease. 12 In addition, a positive relationship between CAVI and CVD risk factors has been reported.…”

Section: Introductionmentioning

confidence: 99%

Effect of vildagliptin, a dipeptidyl peptidase-4 inhibitor, on parameters of glucose metabolism and cardio-ankle vascular index (CAVI) in individuals with type 2 diabetes

Nagayama,

Kawana,

Watanabe

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Dipeptidyl peptidase-4 (DPP-4) inhibitors are the most frequently used first-line agents for the treatment of type 2 diabetes in Japan. This study aimed to examine the effects of vildagliptin, a DPP-4 inhibitor, on glucose metabolism and arterial stiffness. Methods Twenty treatment-naïve patients with type 2 diabetes (8 males and 12 females) received vildagliptin 50 mg twice daily for 6 months. Self-monitored blood glucose measurements and a 75-g oral glucose tolerance test (OGTT) were performed during the study. Systemic arterial stiffness was assessed using the cardio-ankle vascular index (CAVI). Results After 6 months of vildagliptin treatment, a significant decrease in median HbA1c (from 8.3 to 6.4%, p < 0.001) and γ-GTP (from 25 to 19 IU/L, p < 0.001), an increase in fasting HOMA-β (from 26.1 to 34.5%, p = 0.013), and a marginally significant decrease in CAVI (from 8.9 to 8.4, p = 0.087) were observed. The glycemic variability parameters also improved, whereas insulin sensitivity and oxidative stress remained unchanged. Participants with lower glycemic variability in the 75-g OGTT after 6 months of vildagliptin treatment showed a significant decrease in CAVI. The baseline BMI was significantly higher in participants with decreased CAVI than in those with no change in CAVI (24.5 vs. 20.8 kg/m2, p = 0.047). Conclusions After 6 months of vildagliptin treatment, glucose metabolism parameters including insulin secretion improved. A decrease in the CAVI was also observed, especially in individuals with improved glycemic variability in the 75-g OGTT. Vildagliptin may be suitable for vascular protection in individuals with high glycemic variability and/or an elevated BMI.

show abstract

PP.20.15

Cited by 2 publications

References 0 publications

Impacts of Metabolic Syndrome Scores on Cerebrovascular Conductance Are Mediated by Arterial Stiffening

Impacts of Metabolic Syndrome Scores on Cerebrovascular Conductance Are Mediated by Arterial Stiffening

Effect of vildagliptin, a dipeptidyl peptidase-4 inhibitor, on parameters of glucose metabolism and cardio-ankle vascular index (CAVI) in individuals with type 2 diabetes

Contact Info

Product

Resources

About